SCHEMBL4242986

SCHEMBL4242986

CC(CC(N)=O)N1CCC(N(Cc2cccc(C#N)c2)c2ccc(NS(C)(=O)=O)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 14/20 0.54
F10 P00742 2/20 0.41
KCNH2 Q12809 1/20 0.40
NR3C1 P04150 1/20 0.39
SLC6A2 P23975 2/20 0.38
SLC6A4 P31645 2/20 0.38
SLC6A3 Q01959 2/20 0.38
UBE2M P61081 1/20 0.38
DCUN1D1 Q96GG9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4244689 0.89 CCR5 (0.56) CCR5KCNH2SLC6A2SLC6A4SLC6A3
SCHEMBL4236454 0.89 CCR5 (0.56) CCR5KCNH2SLC6A2SLC6A4SLC6A3
SCHEMBL4242988 0.89 CCR5 (0.56) CCR5F10NR3C1SLC6A2SLC6A4
SCHEMBL4241155 0.87 CCR5 (0.57) CCR5F10KCNH2SLC6A2SLC6A4
SCHEMBL4242902 0.87 CCR5 (0.57) CCR5F10KCNH2SLC6A2SLC6A4
SCHEMBL4244475 0.87 CCR5 (0.54) CCR5F10KCNH2SLC6A2SLC6A4
SCHEMBL4244485 0.87 CCR5 (0.54) CCR5KCNH2SLC6A2SLC6A4SLC6A3
SCHEMBL4248686 0.87 CCR5 (0.56) CCR5F10KCNH2SLC6A2SLC6A4
SCHEMBL4244944 0.86 CCR5 (0.56) CCR5F10KCNH2SLC6A2SLC6A4
SCHEMBL4244745 0.86 CCR5 (0.55) CCR5KCNH2UBE2MDCUN1D1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7491735-B2 Chemokine receptor binding compounds GENZYME CORPORATION (US) 2009-02-17 US claimed
EP-1708703-A4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC (CA) 2008-04-09 EP claimed
EP-1708703-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2006-10-11 EP claimed
US-20050277670-A1 Chemokine receptor binding compounds ANORMED INC. 2005-12-15 US claimed
WO-2005059107-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2005-06-30 WO claimed
US-7491735-B2 Chemokine receptor binding compounds GENZYME CORPORATION (US) 2009-02-17 US disclosed
EP-1708703-A4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC (CA) 2008-04-09 EP disclosed
EP-1708703-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2006-10-11 EP disclosed
US-20050277670-A1 Chemokine receptor binding compounds ANORMED INC. 2005-12-15 US disclosed
WO-2005059107-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277670-A1 Chemokine receptor binding compounds CCR5, CXCR3, CCL5 CCR5 1/4885F10 4090/4885KCNH2 4679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.